Novo Nordisk A/S (NVO)

Novo Nordisk said on Thursday it would buy U.S.-based Akero Therapeutics for up to $5.2 billion to add its promising experimental liver disease drug, in the first major deal by the Danish drugmaker's ...

Novo Nordisk A/S (NYSE:NVO) is down 1% to trade at $59 this morning, after news surfaced that the pharmaceutical concern has entered an agreement to purchase U.S.-based peer Akero Therapeutics Inc (NA...

Novo Nordisk A/S (NYSE:NVO) agreed on Thursday to acquire Akero Therapeutics, Inc. (NASDAQ:AKRO) focused on metabolic diseases.

Novo Nordisk (NYSE:NVO) announced it is acquiring Akero Therapeutics (NASDAQ: AKRO) for a total potential value of up to $5.2 billion, strengthening its pipeline in treatments for metabolic dysfunctio...

Novo said it would buy Akero for $54 a share in cash and an additional $6 if it gets U.S. approval of Efruxifermin - it's treatment for fatty liver disease.

Novo Nordisk, the Danish drugmaker behind Ozempic and other weight-loss drugs, said it's paying up to $5.2 billion to buy Akero Therapeutics, a biotech with a drug in a late-stage trial to treat a fat...

Novo said the acquisition of would contribute to its strategy to develop medicines for people living with diabetes, obesity and their associated comorbidities.

Danish drugmaker Novo Nordisk said on Thursday it had agreed to buy United States based Akero Therapeutics, a clinical-stage company developing innovative treatments for patients with serious metaboli...

On October 07, 2025, Carolina Wealth Advisors, LLC disclosed a buy of Novo Nordisk A/S (NYSE: NVO) shares, an estimated $6.01 million trade based on the average price for Q3 2025.

Amazon (AMZN) launches Prime Big Deal Days, kicking off early holiday shopping with exclusive offers and increased competition from Target and Walmart. Novo Nordisk (NVO) cuts dozens of production job...